RS50831B - Izolovano antitelo ili fragment antitela koji se specifično vezuju za rg1 polipeptid - Google Patents
Izolovano antitelo ili fragment antitela koji se specifično vezuju za rg1 polipeptidInfo
- Publication number
- RS50831B RS50831B YUP-446/02A YUP44602A RS50831B RS 50831 B RS50831 B RS 50831B YU P44602 A YUP44602 A YU P44602A RS 50831 B RS50831 B RS 50831B
- Authority
- RS
- Serbia
- Prior art keywords
- polypeptide
- amino acid
- antibody
- specifically binds
- antibody fragment
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 3
- 230000001419 dependent effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Izolovano antitelo ili fragment antitela koji se specifično vezuju za RG1 polipeptid iz SEQ ID NO: 2, naznačeni time, stoje polipeptid odabran od grupe koja se sastoji od:(a) polipeptida koji se sastoji od amino kiseline 28 do amino kiseline 46 kako je to dato na Slici 2 (SEQ ID NO: 2); i(b) polipeptida koji se sastoji od amino kiseline 28 do amino kiseline 46 i amino kiseline 77 do amino kiseline 91 kako je to dato na Slici 2 (SEQ ID NO: 2).Prijava sadrži još 5 nazavisnih i 7 zavisnih patentnih zahteva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17237099P | 1999-12-16 | 1999-12-16 | |
| US09/732,357 US6682902B2 (en) | 1999-12-16 | 2000-12-07 | DNA encoding a novel RG1 polypeptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| YU44602A YU44602A (sh) | 2005-06-10 |
| RS50831B true RS50831B (sr) | 2010-08-31 |
Family
ID=26868022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YUP-446/02A RS50831B (sr) | 1999-12-16 | 2000-12-15 | Izolovano antitelo ili fragment antitela koji se specifično vezuju za rg1 polipeptid |
Country Status (32)
| Country | Link |
|---|---|
| US (5) | US6682902B2 (sr) |
| EP (2) | EP1237915B1 (sr) |
| JP (1) | JP4979867B2 (sr) |
| KR (1) | KR100752434B1 (sr) |
| CN (1) | CN1297566C (sr) |
| AT (1) | ATE440862T1 (sr) |
| AU (1) | AU784674B2 (sr) |
| BG (1) | BG65898B1 (sr) |
| BR (1) | BR0017022A (sr) |
| CA (1) | CA2394574A1 (sr) |
| CZ (1) | CZ299232B6 (sr) |
| DE (1) | DE60042836D1 (sr) |
| DK (1) | DK1237915T3 (sr) |
| EE (1) | EE05293B1 (sr) |
| ES (1) | ES2331106T3 (sr) |
| HR (1) | HRP20020549B1 (sr) |
| HU (1) | HU229001B1 (sr) |
| IL (2) | IL150115A0 (sr) |
| LT (1) | LT5046B (sr) |
| ME (1) | MEP37808A (sr) |
| MX (1) | MXPA02005914A (sr) |
| NO (1) | NO330924B1 (sr) |
| NZ (1) | NZ519598A (sr) |
| PL (1) | PL207634B1 (sr) |
| PT (1) | PT1237915E (sr) |
| RO (1) | RO122543B1 (sr) |
| RS (1) | RS50831B (sr) |
| RU (1) | RU2283130C2 (sr) |
| SI (2) | SI1237915T1 (sr) |
| SK (2) | SK286384B6 (sr) |
| WO (1) | WO2001044291A2 (sr) |
| ZA (1) | ZA200205638B (sr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020161199A1 (en) * | 1998-04-08 | 2002-10-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| NZ528700A (en) * | 1998-04-08 | 2005-02-25 | Genentech Inc | Novel PRO866 polypeptides and nucleic acids with homology to mindin and spondin proteins |
| US6960433B1 (en) | 1998-10-19 | 2005-11-01 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
| US20070031901A1 (en) * | 1999-03-08 | 2007-02-08 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| US6682902B2 (en) * | 1999-12-16 | 2004-01-27 | Schering Aktiengesellschaft | DNA encoding a novel RG1 polypeptide |
| BRPI0412245A (pt) * | 2003-07-22 | 2006-09-19 | Schering Ag | anticorpos de rg1 e usos destes |
| US7294704B2 (en) | 2003-08-15 | 2007-11-13 | Diadexus, Inc. | Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk |
| US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| TWI596109B (zh) * | 2007-02-21 | 2017-08-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| AU2008331507A1 (en) * | 2007-11-30 | 2009-06-11 | Bristol-Myers Squibb Company | Conjugates of anti-RG-1 antibodies |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| CN102346184B (zh) * | 2010-08-03 | 2014-03-26 | 中国人民解放军军事医学科学院生物工程研究所 | Spon2的新用途 |
| DE102012016127A1 (de) | 2011-08-31 | 2013-02-28 | Daniel Elias | Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5246692A (en) * | 1986-09-05 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US4831175A (en) * | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
| US5437994A (en) | 1989-06-15 | 1995-08-01 | Regents Of The University Of Michigan | Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU687001B2 (en) | 1992-05-14 | 1998-02-19 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting cancer development |
| US5871969A (en) | 1996-02-12 | 1999-02-16 | Human Genome Sciences, Inc. | Nucleic acids encoding human neuronal attachment factor-1 |
| US5804382A (en) | 1996-05-10 | 1998-09-08 | Beth Israel Deaconess Medical Center, Inc. | Methods for identifying differentially expressed genes and differences between genomic nucleic acid sequences |
| US6287777B1 (en) * | 1996-05-10 | 2001-09-11 | Beth Israel Deaconess Medical Center | NPG-1 gene that is differentially expressed in prostate tumors |
| US6177244B1 (en) * | 1996-05-10 | 2001-01-23 | Beth Israel Deaconess Medical Center Inc. | NPG-1 gene that is differentially expressed in prostate tumors |
| JP3494529B2 (ja) * | 1996-06-06 | 2004-02-09 | Ｙｋｋ株式会社 | 一体成形面ファスナー |
| JP4065326B2 (ja) * | 1996-08-26 | 2008-03-26 | ユニバーシティ・オブ・ワシントン | パーレカンドメインｉスプライシング変異体の治療および診断への利用 |
| AU6961398A (en) | 1997-04-10 | 1998-10-30 | Zymogenetics Inc. | Secreted f-spondin homologs |
| EP0981625A2 (en) * | 1997-05-06 | 2000-03-01 | Human Genome Sciences, Inc. | $i(ENTEROCOCCUS FAECALIS) POLYNUCLEOTIDES AND POLYPEPTIDES |
| AU7376698A (en) | 1997-05-09 | 1998-11-27 | Smithkline Beecham Corporation | Integrin ligand, human mindin |
| DK1490386T3 (da) | 1998-03-10 | 2008-12-15 | Genentech Inc | Nyt polypeptid og nukleinsyrer kodende for dette |
| US6166176A (en) * | 1998-03-17 | 2000-12-26 | Immvarx, Inc. | Cancer marker protein and peptides thereof |
| US6960433B1 (en) * | 1998-10-19 | 2005-11-01 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
| WO2000023108A1 (en) | 1998-10-19 | 2000-04-27 | Diadexus Llc | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
| US6682736B1 (en) * | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US6824780B1 (en) * | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
| US6682902B2 (en) * | 1999-12-16 | 2004-01-27 | Schering Aktiengesellschaft | DNA encoding a novel RG1 polypeptide |
-
2000
- 2000-12-07 US US09/732,357 patent/US6682902B2/en not_active Expired - Fee Related
- 2000-12-15 ES ES00990937T patent/ES2331106T3/es not_active Expired - Lifetime
- 2000-12-15 NZ NZ519598A patent/NZ519598A/en not_active IP Right Cessation
- 2000-12-15 BR BR0017022-4A patent/BR0017022A/pt not_active Application Discontinuation
- 2000-12-15 WO PCT/US2000/033901 patent/WO2001044291A2/en active Application Filing
- 2000-12-15 JP JP2001544779A patent/JP4979867B2/ja not_active Expired - Fee Related
- 2000-12-15 EP EP00990937A patent/EP1237915B1/en not_active Expired - Lifetime
- 2000-12-15 HU HU0204224A patent/HU229001B1/hu not_active IP Right Cessation
- 2000-12-15 IL IL15011500A patent/IL150115A0/xx unknown
- 2000-12-15 CN CNB008190518A patent/CN1297566C/zh not_active Expired - Fee Related
- 2000-12-15 SK SK848-2002A patent/SK286384B6/sk not_active IP Right Cessation
- 2000-12-15 CA CA002394574A patent/CA2394574A1/en not_active Abandoned
- 2000-12-15 PL PL356220A patent/PL207634B1/pl unknown
- 2000-12-15 AT AT00990937T patent/ATE440862T1/de active
- 2000-12-15 RU RU2002119208/15A patent/RU2283130C2/ru not_active IP Right Cessation
- 2000-12-15 ME MEP-378/08A patent/MEP37808A/xx unknown
- 2000-12-15 SI SI200031038T patent/SI1237915T1/sl unknown
- 2000-12-15 MX MXPA02005914A patent/MXPA02005914A/es active IP Right Grant
- 2000-12-15 SI SI200020058A patent/SI21140A/sl not_active IP Right Cessation
- 2000-12-15 SK SK5055-2008A patent/SK288147B6/sk not_active IP Right Cessation
- 2000-12-15 AU AU30746/01A patent/AU784674B2/en not_active Ceased
- 2000-12-15 EE EEP200200323A patent/EE05293B1/xx not_active IP Right Cessation
- 2000-12-15 DK DK00990937T patent/DK1237915T3/da active
- 2000-12-15 PT PT00990937T patent/PT1237915E/pt unknown
- 2000-12-15 RS YUP-446/02A patent/RS50831B/sr unknown
- 2000-12-15 CZ CZ20022037A patent/CZ299232B6/cs not_active IP Right Cessation
- 2000-12-15 EP EP08163898A patent/EP2048157B1/en not_active Expired - Lifetime
- 2000-12-15 RO ROA200200857A patent/RO122543B1/ro unknown
- 2000-12-15 DE DE60042836T patent/DE60042836D1/de not_active Expired - Lifetime
- 2000-12-15 KR KR1020027007708A patent/KR100752434B1/ko not_active IP Right Cessation
-
2002
- 2002-06-10 IL IL150115A patent/IL150115A/en not_active IP Right Cessation
- 2002-06-13 BG BG106823A patent/BG65898B1/bg unknown
- 2002-06-14 NO NO20022836A patent/NO330924B1/no not_active IP Right Cessation
- 2002-06-24 LT LT2002070A patent/LT5046B/lt not_active IP Right Cessation
- 2002-06-24 HR HRP20020549AA patent/HRP20020549B1/hr not_active IP Right Cessation
- 2002-07-15 ZA ZA200205638A patent/ZA200205638B/xx unknown
-
2003
- 2003-07-08 US US10/616,279 patent/US7307154B2/en not_active Expired - Fee Related
- 2003-07-22 US US10/624,884 patent/US20040152139A1/en not_active Abandoned
-
2007
- 2007-10-30 US US11/981,132 patent/US7893217B2/en not_active Expired - Fee Related
- 2007-10-30 US US11/981,240 patent/US7887804B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS51635B (sr) | Antitela koja blokiraju cripto i njihova upotreba | |
| RS52769B (sr) | Kompozicije i postupci za povećanje mineralizacije kostiju | |
| RS50831B (sr) | Izolovano antitelo ili fragment antitela koji se specifično vezuju za rg1 polipeptid | |
| YU9403A (sh) | Anti-dualna antitela integrina, kompozicije, postupci i primene | |
| DE69222956D1 (de) | Kleinste erkennungseinheit eines pem-mucin-"tandem repeat"-spezifischen monoklonalen antikoerpers | |
| RS51898B (sr) | Specifični agensi koji vezuju humani angiopoetin-2 | |
| AR001731A1 (es) | Nueva celulasa método para producirla composición que la contiene vector que comprende al adn que lacodifica celula huesped método de aplicación | |
| MX336118B (es) | Expresion hibrida y en tandem de proteinas de neisseria. | |
| RS51157B (sr) | Baff receptor (bcma), imunoregulatorni agens | |
| ATE263157T1 (de) | Nematizide trifluorbutene | |
| IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
| RS54133B1 (sr) | Anti-il-6 antitela, preparati, postupci pripreme i upotrebe | |
| DE60030769D1 (de) | Verfahren zur behandlung von entzündungen | |
| DK0758383T3 (da) | Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof | |
| RS50426B (sr) | Tenascin -c ligandi nukleinske kiseline | |
| RS50926B (sr) | Upotreba il-18 inhibitora za lečenje i/ili prevenciju ateroskleroze | |
| DE60233532D1 (de) | An proteinphosphatase 2a bindende synthetische ode anwendungen | |
| ATE343369T1 (de) | Neue verwendung von proteinhydrolysaten | |
| ATE301714T1 (de) | Insulinartigen wachstumsfaktor bindendes protein -3 variante | |
| DE60118935D1 (de) | Dna & protein bindende miniatur proteine | |
| SE0302103D0 (sv) | Xylanases with enhanced thermophilicity and alkalophilicity | |
| ES2185628T3 (es) | Procedimiento para preparar proteinas modificadas. | |
| BR9711540A (pt) | Inibidores de protease proteìnico estabilizados e variantes dos mesmos | |
| ATE435034T1 (de) | Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist. | |
| SE9602822D0 (sv) | New receptor |